INVA
INVA
NASDAQ · Pharmaceuticals

Innoviva Inc

$24.08
+0.53 (+2.25%)
Financial Highlights (FY 2026)
Revenue
358.82M
Net Income
236.55M
Gross Margin
74.8%
Profit Margin
65.9%
Rev Growth
+7.5%
D/E Ratio
0.22
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 358.82M 333.85M 296.49M 325.02M
Gross Profit 268.40M 249.72M 199.68M 218.90M
Operating Income 142.85M 119.62M 108.77M 141.90M
Net Income 236.55M 198.08M 100.45M 107.69M
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Rev Growth +7.5% +7.5% +12.4% +2.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 149.50M 149.50M 569.66M 644.56M
Total Equity 680.48M 680.48M 1.17B 1.19B
D/E Ratio 0.22 0.22 0.49 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 155.02M 137.02M 161.71M 177.91M
Free Cash Flow 84.32M 106.96M